Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
60,301.98 -1,263.23 (-2.05%) CMC Crypto 200
1,257.96 -25.86 (-2.01%)
PFE Aug 2024 33.000 call
| Previous close | 0.0300 |
| Open | 0.0400 |
| Bid | 0.0100 |
| Ask | 0.0500 |
| Strike | 33.00 |
| Expiry date | 2024-08-02 |
| Day's range | 0.0300 - 0.0400 |
| Contract range | N/A |
| Volume | |
| Open interest | 104 |
- Yahoo Finance Video
How Medicare drug price negotiations could hit pharma stocks
As a string of negative headlines and promising new developments present ideal buying opportunities for investors, Josh Lipton and Julie Hyman perform a mid-year check on the pharmaceutical industry. Goldman Sachs senior biotechnology analyst Chris Shibutani joins Market Domination to break down the health of the pharmaceutical large-caps and unrecognized areas of opportunity in the sector. Shibutani says the industry is "quite healthy," but acknowledges there are always "cross currents." He points to "tremendous advancements" in biotechnology innovation rising to daunting unmet needs, from cancer to cardiovascular disease. The analyst points to "holy grail-like" opportunities such as obesity drugs, and notes improvements in chemotherapy and next-generation antibody-drug conjugates for cancer treatment. However, Shibutani explains that the Inflation Reduction Act may challenge the industry, as the landmark legislation stipulates drug price negotiation for Medicare that is "beginning to play out." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
ZacksCDC Narrows Age Recommendation for Use of RSV Vaccine
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
ZacksPfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
